

Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/L3B58AD41436EN.html>

Date: October 2020

Pages: 37

Price: US\$ 3,500.00 (Single User License)

ID: L3B58AD41436EN

Abstracts

Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2020'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 9 molecules.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

The report 'Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2020' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5 and 1 respectively. Report covers products from therapy areas Respiratory, Gastrointestinal, Metabolic Disorders, Genito Urinary System And Sex Hormones, Immunology, Male Health, Musculoskeletal Disorders, Oncology and Toxicology which include indications Diabetic Nephropathy, Idiopathic Pulmonary Fibrosis, Non-Alcoholic

Steatohepatitis (NASH), Pulmonary Fibrosis, Benign Prostatic Hyperplasia, Diarrhea, Fibrosis, Kidney Fibrosis, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Systemic Sclerosis (Scleroderma) and Triple-Negative Breast Cancer (TNBC).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)

The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Overview

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Curadim Pharma Co Ltd

Horizon Therapeutics Plc

Novo Nordisk AS

Ono Pharmaceutical Co Ltd

RxBio Inc

Takeda Pharmaceutical Co Ltd

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Drug Profiles

BMS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-2090 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
EPGN-696 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HZN-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7300243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize LPA1 for Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-615 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Dormant Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Discontinued Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -
Product Development Milestones
Featured News & Press Releases
Sep 28, 2011: RxBio Receives \$15m BARDA Contract For Development Of Rx100 To
Protect Against Radiation
Appendix
Methodology
Coverage

Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Bristol-Myers Squibb Co, H2 2020

Pipeline by Curadim Pharma Co Ltd, H2 2020

Pipeline by Horizon Therapeutics Plc, H2 2020

Pipeline by Novo Nordisk AS, H2 2020

Pipeline by Ono Pharmaceutical Co Ltd, H2 2020

Pipeline by RxBio Inc, H2 2020

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

I would like to order

Product name: Lysophosphatidic Acid Receptor 1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/L3B58AD41436EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L3B58AD41436EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970